Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 6, 2009, Pages 442-444

  Haidar, Ali ^a   Jønler, Morten ^a   Folkmar, Troels B ^a   Lund, Lars ^a  

^a VIBORG HOSPITAL   (Denmark)

Author keywords

Bisphosphonate; Osteonecrosis; Prostate cancer; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; FEMALE; HUMAN; JAW DISEASE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; METASTASIS; MORBIDITY; PAIN; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; FACIAL BONES; FEMALE; HUMANS; INCIDENCE; JAW DISEASES; KIDNEY NEOPLASMS; MALE; MAXILLA; MIDDLE AGED; OSTEONECROSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 72049116055     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365590903295193     Document Type: Article

References (23)

1. Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2009;38:5-9.
2. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91: 968-971
3. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008;13:911-920
4. Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998;20:206-213
5. Russell RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25;97-106.
6. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;:24(Suppl 5):73-79
7. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007;1:14-20.
8. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007;6:305-313
9. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-1867
10. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther 2007;4:92-100.
11. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
12. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441
13. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, doubleblind placebo-controlled multicenter study. Anticancer Res 1999;19:3383-3392
14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
15. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and treatment. Annu Rev Med 2009;60:85-96.
16. Abildgaard N, Gregersen H, Lund T, Marker P, Preiss B, Schiødt, et al. Bifosfonate-associeret osteonekrose i kæberne hos patientermedmyelomatose. 2007; 1-5.www.kaebekirurgi. dk.
17. Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma. Ugeskr Laeger 2009;171: 50-52
18. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphonates. N Engl J Med 2005;353:99.
19. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
20. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791
21. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23: 826-836
22. FelsenbergD,HoffmeisterB.Necrosisof thejawafter high-dose bisphosphonate therapy. Dtsch Arzteblatt 2006;103:3078.
23. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009;67:2-12.